SCHEMBL4864531

SCHEMBL4864531

COc1ccc(OCC(O)CN2CCNCC2)cc1

nearest known ligand 0.97

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.74
POLB P06746 1/20 0.74
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
L3MBTL1 Q9Y468 2/20 0.63
MAPK1 P28482 1/20 0.63
GLA P06280 1/20 0.62
USP2 O75604 1/20 0.62
TSHR P16473 1/20 0.62
MAPT P10636 3/20 0.62
ATM Q13315 1/20 0.61
CYP2D6 P10635 1/20 0.60
CYP2C19 P33261 1/20 0.60
DRD4 P21917 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4578208 0.90 KDM4E (0.85) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL6754439 0.89 USP2 (0.81) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL4866196 0.87 TP53 (0.73) KDM4EMEN1KMT2AL3MBTL1MAPK1
SCHEMBL20444278 0.86 KMT2A (0.76) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL7297907 0.86 KCNH2 (0.71) KDM4EKMT2AMAPK1GLAUSP2
SCHEMBL12402885 0.86 ATM (0.61) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL5754770 0.86 TSHR (0.67) KDM4EPOLBMEN1KMT2AGLA
SCHEMBL12402888 0.86 ATM (0.61) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL31094186 0.86 KDM4E (0.56) KDM4EPOLBMEN1KMT2AL3MBTL1
SCHEMBL24322808 0.85 L3MBTL1 (0.77) KDM4EPOLBMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
US-7056924-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-06-06 US disclosed
US-7001909-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-02-21 US disclosed
US-20050260518-A1 Heat sensitive recording material and microcapsule FUJI PHOTO FILM CO., LTD. 2005-11-24 US disclosed
EP-1583760-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV Therapeutics Inc. (US) 2005-10-12 EP disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-6930111-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2005-08-16 US disclosed
US-20010019806-A1 Azomethine dye precursor, image-forming material, and image-forming method FUJIFILM CORPORATION (JP) 2001-09-06 US disclosed
US-5935757-A HIGH COLOR DEVELOPING SENSITIVITY AND EXCELLENT STORABILITY. USING AN ESTER- OR AMIDE CONTAINING SULFOAMIDOBENZENE IN A LAYER CONTAINING A DIAZONIUM SALT AND A REACTIVE COUPLER FUJI PHOTO FILM CO., LTD. (JP) 1999-08-10 US disclosed
US-5925489-A CONTAINING DIAZONIUM SALT AND PYRROLOPYRIMIDINE COUPLER WHICH REACT WHEN HEATED TO DEVELOP VIOLET TO CYAN COLORS, IMAGE QUALITY AND STABILITY, SHELF LIFE FUJI PHOTO FILM CO., LTD. (JP) 1999-07-20 US disclosed
US-5866293-A CONTAINING DIAZO COMPOUND AND PYRAZOLONE COUPLER; STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1999-02-02 US disclosed
EP-0327318-B1 Heat-sensitive recording materials FUJI PHOTO FILM CO LTD (JP) 1995-07-19 EP disclosed
EP-0337734-B1 Heat-developable diazo copying material FUJI PHOTO FILM CO LTD (JP) 1995-03-08 EP disclosed
EP-0327318-A2 Heat-sensitive recording materials FUJI PHOTO FILM CO., LTD. (JP) 1989-08-09 EP disclosed
US-4567264-A ADRENERGIC BLOCKING AGENTS SYNTEX (U.S.A.) INC. (US) 1986-01-28 US disclosed
EP-0126449-A1 Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry SYNTEX (U.S.A.) INC. (US) 1984-11-28 EP disclosed
US-4269838-A ADRENERGIC BLOCKING AGENTS; ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS NIPPON SHINYAKU CO. LTD. (JP) 1981-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A KDM4E 2949/4885POLB 2485/4885MEN1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.